» Articles » PMID: 34513807

Advances in Nanomaterials for Injured Heart Repair

Overview
Date 2021 Sep 13
PMID 34513807
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Atherosclerotic cardiovascular disease (ASCVD) is one of the leading causes of mortality worldwide. Because of the limited regenerative capacity of adult myocardium to compensate for the loss of heart tissue after ischemic infarction, scientists have been exploring the possible mechanisms involved in the pathological process of ASCVD and searching for alternative means to regenerate infarcted cardiac tissue. Although numerous studies have pursued innovative solutions for reversing the pathological process of ASCVD and improving the effectiveness of delivering therapeutics, the translation of those advances into downstream clinical applications remains unsatisfactory because of poor safety and low efficacy. Recently, nanomaterials (NMs) have emerged as a promising new strategy to strengthen both the efficacy and safety of ASCVD therapy. Thus, a comprehensive review of NMs used in ASCVD treatment will be useful. This paper presents an overview of the pathophysiological mechanisms of ASCVD and the multifunctional mechanisms of NM-based therapy, including antioxidative, anti-inflammation and antiapoptosis mechanisms. The technological improvements of NM delivery are summarized and the clinical transformations concerning the use of NMs to treat ASCVD are examined. Finally, this paper discusses the challenges and future perspectives of NMs in cardiac regeneration to provide insightful information for health professionals on the latest advancements in nanotechnologies for ASCVD treatment.

Citing Articles

Fetal adnexa-derived allogeneic mesenchymal stem cells for cardiac regeneration: the future trend of cell-based therapy for age-related adverse conditions.

Gorjipour F, Bohloolighashghaei S, Sotoudeheian M, Pazoki Toroudi H Hum Cell. 2025; 38(2):61.

PMID: 39998714 DOI: 10.1007/s13577-025-01190-2.


A novel degradable PEG superparamagnetic iron oxide capsule coupled with a polyphenolic nano-enzymatic conjugate (PSPM-NE), to treat ROS-driven cardiovascular-diseases, tested in atherosclerosis as a model disease, and hypothesizing autoimmunity as....

Pereira G Front Cardiovasc Med. 2024; 11:1125571.

PMID: 39145281 PMC: 11323396. DOI: 10.3389/fcvm.2024.1125571.

References
1.
Labatut A, Mattheolabakis G . Non-viral based miR delivery and recent developments. Eur J Pharm Biopharm. 2018; 128:82-90. PMC: 5984722. DOI: 10.1016/j.ejpb.2018.04.018. View

2.
Zhu L, Tian T, Wang J, He J, Chen T, Pan M . Hypoxia-elicited mesenchymal stem cell-derived exosomes facilitates cardiac repair through miR-125b-mediated prevention of cell death in myocardial infarction. Theranostics. 2019; 8(22):6163-6177. PMC: 6299684. DOI: 10.7150/thno.28021. View

3.
Zhang C, Shao K, Liu C, Li C, Yu B . Hypoxic preconditioning BMSCs-exosomes inhibit cardiomyocyte apoptosis after acute myocardial infarction by upregulating microRNA-24. Eur Rev Med Pharmacol Sci. 2019; 23(15):6691-6699. DOI: 10.26355/eurrev_201908_18560. View

4.
Nie J, Qiao B, Duan S, Xu C, Chen B, Hao W . Unlockable Nanocomplexes with Self-Accelerating Nucleic Acid Release for Effective Staged Gene Therapy of Cardiovascular Diseases. Adv Mater. 2018; 30(31):e1801570. DOI: 10.1002/adma.201801570. View

5.
Lai T, Lee T, Chang Y, Chen Y, Lin S, Lin S . MicroRNA-221/222 Mediates ADSC-Exosome-Induced Cardioprotection Against Ischemia/Reperfusion by Targeting PUMA and ETS-1. Front Cell Dev Biol. 2020; 8:569150. PMC: 7744807. DOI: 10.3389/fcell.2020.569150. View